arrow
J

Jacob B. Schwarz

rapt therapeutics
H指数:27
被引数:3,005

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery and Characterization of Zelnecirnon (RPT193); a Potent and Selective CCR4 Antagonist for Allergic Disorders
2026-01-230
PRE
Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model
2024-05-150
PRE
Lipid Tales: Optimizing Arylomycin Membrane Anchors
2023-10-113
PRE
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy
2022-09-206
PRE
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo
2020-10-0223
OAAI
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity
2020-04-1750
PREAI
GluN2A NMDA Receptor Enhancement Improves Brain Oscillations, Synchrony, and Cognitive Functions in Dravet Syndrome and Alzheimer's Disease Models
2020-01-0156
OAAI
Discovery of potent and selective inhibitors of USP7 with anti-tumor activity in vitro and in vivo
2019-07-011
PRE
Discovery and optimization of potent and selective inhibitors of USP7 to enhance anti-tumor immunity and target tumor growth
2018-07-010
PRE
GluN2A-Selective Pyridopyrimidinone Series of NMDAR Positive Allosteric Modulators with an Improved in Vivo Profile
2016-11-0836
OAAI
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
2016-06-07128
OAAI
Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design
2016-03-0888
PREAI